PF-184563

PF-184563

220px
Systematic (IUPAC) name
8-Chloro-5-methyl-1-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene
Pharmacokinetic data
Bioavailability	34%
Protein binding	69%
Biological half-life	1.8h
Identifiers
CAS Number	748806-39-5 Y
ATC code	none
ChemSpider	9412479 N
ChEMBL	CHEMBL1837037 N
Chemical data
Formula	C21H23ClN6
Molecular mass	394.91
SMILES CN1CC2=C(C=CC(=C2)Cl)N3C(=NN=C3C4CCN(CC4)C5=CC=CC=N5)C1
InChI InChI=1S/C21H23ClN6/c1-26-13-16-12-17(22)5-6-18(16)28-20(14-26)24-25-21(28)15-7-10-27(11-8-15)19-4-2-3-9-23-19/h2-6,9,12,15H,7-8,10-11,13-14H2,1H3 N Key:LXHAZNJVVVBJIF-UHFFFAOYSA-N N
NY (what is this?)  (verify)

PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor. The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.